



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/13, C07K 16/40, 16/46, 17/00, A61K 39/395, 33/06, 38/19 // (A61K 39/395, 33:06) (A61K 39/395, 38:19)</p>	A1	<p>(11) International Publication Number: WO 95/34652</p> <p>(43) International Publication Date: 21 December 1995 (21.12.95)</p>
<p>(21) International Application Number: PCT/US95/07372</p> <p>(22) International Filing Date: 9 June 1995 (09.06.95)</p> <p>(30) Priority Data: 259,321 10 June 1994 (10.06.94) US</p> <p>(71) Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Street, Oklahoma City, OK 73104 (US).</p> <p>(72) Inventors: REZAIIE, Alireza; 1216 S.E. Twelfth Street, Moore, OK 73160 (US). ESMON, Charles, T.; 5800 North Stonewall, Oklahoma City, OK 73111 (US).</p> <p>(74) Agent: PABST, Patrea, L.; Amall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).</p>	<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: CALCIUM BINDING RECOMBINANT ANTIBODY AGAINST PROTEIN C</p>		
<p>(57) Abstract</p> <p>A Ca²⁺ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin, in purification of Protein C, and in treatment of tumors.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**CALCIUM BINDING RECOMBINANT ANTIBODY AGAINST
PROTEIN C**

Background of the Invention

This invention is generally in the area
5 of antibodies to plasma proteins, specifically
Protein C, and methods for use thereof.

Protein C is a vitamin K-dependent plasma
protein zymogen to a serine protease. Upon
activation it becomes a potent anticoagulant.
10 Activated protein C acts through the specific
proteolysis of the procoagulant cofactors, factor
VIIIa and factor Va. This activity requires the
presence of another vitamin K-dependent protein,
protein S, calcium and a phospholipid (presumably
15 cellular) surface. As described in Hemostasis and
Thrombosis: Basic Principles and Clinical Practice
2nd Ed., Colman, R.W., et al., p. 263
(J.B.Lippincott, Philadelphia, PA 1987), protein C
circulates in a two-chain form, with the larger,
20 heavy chain bound to the smaller light chain
through a single disulfide link. A small
proportion of the protein also circulates in a
single chain form, where a Lys-Arg dipeptide in the
molecule connects the light chain directly to the
25 heavy chain.

Protein C is activated to activated
protein C (APC). Thrombin is capable of activating
protein C by the specific cleavage of the Arg¹²-Leu¹³
bond in the heavy chain. *In vivo*, in the presence
30 of physiological concentrations of calcium, the
rate of this activation is enhanced dramatically
when thrombin is bound to the endothelial cell
cofactor, thrombomodulin. Matschiner, et al.,
Current Advances in Vitamin K Research, pp. 135-
35 140, John W. Suttie, ed. (Elsevier Science
Publishing Co., Inc. 1988) have further reviewed
the role of the Vitamin K dependent proteins in
coagulation.

Protein C has been shown to have major importance *in vivo*. Patients deficient in protein C, or its cofactor, protein S, show pronounced thrombotic tendencies. Babies born totally
5 deficient in protein C exhibit massive disseminated intravascular coagulation (DIC) and a necrotic syndrome which leads to death within the first few weeks of life if untreated. Activated protein C has also been shown to protect animals against the
10 coagulopathic and lethal effects of endotoxin shock, as described by Taylor, et al., in J. Clin. Invest. 79, 918-925 (1987).

As first reported by Kisiel, in J. Clin. Invest. 64, 761-769 (1979), Protein C was
15 originally isolated in semi-pure form from plasma using classic protein purification techniques, including barium citrate adsorption and elution, ammonium sulfate fractionation, DEAE-Sephadex chromatography, dextran sulfate agarose
20 chromatography, and preparative polyacrylamide gel electrophoresis. This procedure was vastly improved and facilitated by the discovery of a unique antibody to Protein C, designated HPC-4, described by Stearns, et al., in J. Biol. Chem.
25 263(2), 826-832 (1988). As detailed by Esmon, et al., at the Joint IABS/CSL Symposium on Standardization in Blood Fractionation including Coagulation Factors, Melbourne, Australia 1986 (reported in Develop. Biol. Standard., 67, 51-57
30 (S. Karger, Basel, 1987), Protein C can be isolated from human plasma by batch adsorption of diluted heparinized plasma on QAE Sephadex, washing with buffered 0.15 M NaCl and eluting with 0.5 M NaCl, recalcifying and batch adsorbing with HPC-4, then
35 washing with a Ca²⁺ containing buffer and eluting the Protein C with an EDTA containing buffer. HPC-4 is a calcium-dependent monoclonal antibody to

human protein C. The epitope recognized by the antibody has been identified and corresponds to the stretch of amino acids in the zymogen of protein C which spans the thrombin cleavage site. Activated protein C is not recognized by HPC-4. HPC-4 is disclosed and claimed in U.S. Patent No. 5,202,253 to Esmon, et al.

Several antibodies to human protein C have been reported, for example, by Laurell, et al., FEBS Letts. 191(1), 75-81 (1985); Wakabayashi, et al., J. Biol. Chem. 261, 11097-11105 (1986); Sugo, et al., Thromb. Hemost. Abstrs., Brussels, 229 (1987); and Ohlin, et al., J. Biol. Chem. 262, 13798-13804 (1988). Some of these are calcium dependent, for example, one of the antibodies reported by Laurell, et al. However, as far as can be determined in the published reports, this dependence is due to the requirement for calcium binding to the light chain of protein C and the antibodies recognize epitopes on the light chain. Other antibodies recognize the region around the thrombin cleavage site on the heavy chain, but these are not calcium dependent. The HPC-4 antibody of Ohlin, et al., is Ca^{2+} dependent but is not directed against the activation region, and is therefore different from the antibody described in Stearns, et al., and in U.S. Patent No. 5,202,253 to Esmon, et al.

All of the other antibodies that bind to the Ca^{2+} stabilized regions of Protein C recognize both Protein C and the activated form of Protein C. Situations may arise in which the protein uncontaminated by its active form is desirable. This is particularly the case with reference to therapeutic uses of the antibody to inhibit Protein C activation.

Blockage of the natural anticoagulant pathways, in particular the protein C pathway, uses the natural procoagulant properties of the tumor to target the tumor capillaries for microvascular thrombosis, leading to hemorrhagic necrosis of the tumor, as described in U.S. Patent No. 5,147,638 to Esmon, et al. HPC-4 is a preferred antibody for use in this method for the treatment of solid tumors, either alone or in conjunction with biological response modifiers, chemotherapy or radiation treatments.

Tumors contain proteins which predispose to the formation of blood clots in the vessels in the tumor bed. Tumors also contain other proteins and cellular elements which prevent thrombosis of tumor blood vessels. Tumor necrosis results from altering the hemostatic balance between procoagulant and anticoagulant mechanisms to favor thrombosis of the tumor microvasculature. The hemostatic balance of the tumor can be altered by blocking the conversion of protein C to its active form (activated protein C). The procoagulant mechanisms present in the tumor bed will then function without opposition and cause thrombosis of the tumor vessels. The epitope for the HPC-4 antibody spans the activation site in protein C and as a result blocks protein C activation. As an experimental tool it is important to note that the antibody cross-reacts with protein C from canine, porcine and at least two primate plasmas, baboon and marmoset. It does not cross-react with bovine or mouse protein C. The inhibitory effect can be reversed instantly by administration of activated protein C to which the antibody does not bind. The antibody therefore provides a means to selectively inhibit the protein C pathway *in vivo* and to reverse the process if thrombotic complications

ensue at sites other than the tumor. The Protein C blocking agent is preferably administered in combination with a cytokine that stimulates natural killer and lymphokine-activated killer cell-mediated cytotoxicity, activates macrophages, stimulates Fc receptor expression on mononuclear cells and antibody-dependent cellular cytotoxicity, enhances HLA class II antigen expression, and/or stimulates procoagulant activity, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-2 (IL-2), gamma interferon (gamma-IFN), or granulocyte-macrophage colony stimulating factor (GM-CSF). Alternatively, an agent such as endotoxin, or the purified liposaccharide (LPS) from a gram negative bacteria such as *E. coli*, can be used to elicit production of cytokines such as TNF.

HPC-4, despite its wonderful properties, is a murine antibody. It would be advantageous to be able to provide a humanized form of the antibody which is non-immunogenic or less immunogenic. In order to construct a humanized form of HPC-4 it is essential to know the sequence of the hypervariable regions of this antibody. Then using conventional mutagenesis methods developed in molecular biology it is possible to replace the sequence of hypervariable regions of an unrelated human antibody with the sequences of HPC-4 hypervariable regions. Such an approach has been successfully used in the humanization of other antibodies. Furthermore by knowing the sequence of the hypervariable region it may be possible to synthesize short peptides corresponding to the hypervariable regions of the HPC-4 antibody which could mimic HPC-4 and bind to the same region on protein C and prevent activation of protein C by thrombin-thrombomodulin complex. Such peptides

could be very effective in disease states where promoting of the clotting is desired.

It is therefore an object of the present invention to provide a recombinant Ca^{2+} dependent antibody which binds to the activation region of Protein C like HPC-4.

It is a further object of the present invention to provide a DNA sequence encoding the hypervariable region of an antibody like HPC-4.

It is a still further object of the present invention to provide a method and means for using this Ca^{2+} dependent antibody for therapeutic purposes.

It is yet another object of the present invention to provide this Ca^{2+} dependent antibody, antibodies, peptide derivatives and conjugates thereof, for diagnostic purposes.

Summary of the Invention

The amino acid and nucleic acid sequences of the hypervariable regions of the HPC-4 antibody have been determined and used in the construction of "humanized antibodies". Peptides derived from the hypervariable regions are also disclosed which are useful in mimicking HPC-4 - protein C binding. These materials are useful in isolation of protein C, treatment of tumor patients, and as inhibitors of coagulation, as well as in diagnostic assays.

Detailed Description of the Invention

The variable heavy (VH) and the variable light (VL) chains of a Ca^{2+} dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence E D Q V D P R L I D G K (Sequence ID No. 1), in the activation region of the Protein C of non-bovine origin, including human, pig, baboon, and canine Protein C, in

combination with calcium, has been cloned and sequenced. The antibody does not bind to activated protein C ("APC") and can be used to inhibit activation of Protein C by thrombin-thrombomodulin.

5 As described below, the Fab (fragment antigen binding) sequence of the HPC-4 antibody was constructed in a bacterial periplasmic expression vector and the recombinant antibody was isolated from bacterial cell culture supernatants in large

10 quantities by affinity chromatography using the peptide sequence described above bound to an immobilized substrate.

The antibody has a number of specific uses in isolation and characterization of Protein C, as a diagnostic, and as a therapeutic to prevent activation of Protein C. *In vivo*, a humanized recombinant antibody has been demonstrated to inhibit tumor growth. Further, the antibody is effective in promoting clotting in patients having

15 high levels of Factor VIII inhibitors, hemophilia, platelet deficiencies (thrombocytopenia), and other clotting disorders where it is desirable to increase clotting.

Antibody Structure and Specificity

25 X-ray crystallographic studies have provided structures of antibody molecules and have revealed the nature of antigen-antibody recognition. Antibodies are large proteins (approximately 150,000 daltons in the case of an

30 immunoglobulin G), that consist of four polypeptide chains: two identical heavy chains and two identical light chains. The antigen-binding site consists of roughly the first 110 amino acids of the heavy and light chains, and is termed the

35 variable region. Antibodies bind molecules with association constants that range from 10^4 to 10^{14} M⁻¹. Small molecules, typically from 100 to 2500

Daltons, are typically bound in the cleft of the antibody molecule, but for large molecules, for example, from 10 KDa to 500 KDa, the binding site can be an extended surface that can cover 600 to 5 800 Å. The specificity of antibodies for their ligands can exceed that of enzymes for substrates.

Recombinant antibodies are constructed that typically consist of the hypervariable regions of the heavy and light chains of the antibody from 10 which the sequence is derived, in this case HPC-4, which may be crosslinked or coupled to other antibody domains or fusion proteins as discussed in more detail below. The antibody can be modified by site directed mutagenesis of the coding sequence, 15 commonly used in molecular biology to alter affinity or specificity, as well as humanized to improve *in vivo* utility.

HPC-4 Antibody

The properties of the monoclonal 20 antibody, HPC-4, deposited with the American Type Culture Collection, Rockville, MD, on November 2, 1988, and assigned ATCC No. HB 9892, which make it uniquely useful are as follows:

The antibody binds protein C, not 25 activated protein C (APC), and only in the presence of calcium. Thus, when the antibody is immobilized on an affinity support, protein C can be isolated from either plasma-derived sources or from tissue culture expression systems under extremely mild 30 conditions. This is important in maintaining the biological activity of the product and the stability of the solid support resin. Since activated protein C is not bound under any conditions, the resulting product is completely 35 free of APC.

The antibody binds to the activation site on protein C and can therefore be used to block the

formation of the anticoagulant protein APC *in vivo*. Since it does not bind to or inhibit APC, the *in vivo* inhibitory effects can be reversed by administration of APC.

5 Cloning and sequencing of HPC-4 DNA

Methods

Construction of the HPC-4 cDNA Library:

RNA from approximately 1×10^8 HPC-4 hybridoma cells grown in 75 ml T-flasks was prepared and mRNA
10 (PolyA + RNA) was isolated on oligo(dT)-cellulose according to the manufacturer's instruction (Stratagene, CA). Approximately 10 μ g of PolyA + RNA was used to synthesize first and then second-strand cDNA according to established procedures.
15 Using standard molecular biology techniques, *EcoRI* linkers were ligated to double stranded cDNA (ds cDNA) and the ds cDNA ligated to phage lambda (lambda gt10) vector DNA which has been digested with *EcoRI*. The HPC-4 cDNA and lambda gt10 phage
20 vector ligation mixture was packaged *in vitro* and transformed into C600hflA strain of *E. coli*, and plated onto agar plates at high density. The bacteriophage plaques were then transferred to Gene Screen Plus™ filters (New England Nuclear) and
25 probed with 32 P labeled cDNA fragments derived from constant regions of an unrelated immunoglobulin heavy chain (Tasuku Honjo et al, Cell 18:559-568, 1979) and light chain genes (Edward Max et al, J. Biol. Chem. 256:5116-5120, 1981).

30 Several positive clones from heavy chain and light chain plates were identified. Phage DNA were prepared and the inserts were cleaved by the *EcoRI* restriction enzyme. The clones identified by heavy chain or light chain probes gave an insert of
35 approximately 1600 or 800 bp, respectively. The heavy and light chain cDNA fragments were subcloned into *EcoRI* site of pUC19 plasmid and sequenced by

the universal pUC forward and reverse sequencing primers.

Cloning by PCR: The variable regions of heavy (VH) and light chain (VL) of HPC-4 monoclonal antibody were cloned by the PCR method as well. After first strand cDNA synthesis, poly(dG) tail was added to the 3' end of first strand with terminal deoxynucleotidyl transferase (TdT). For cloning of the VH region the product then was amplified with the antisense primer derived from the 3' end of the heavy chain constant region 5'-AAGCGGCCGCTGGATAGACAGATGGGGGTGTCGTTTTGCC-3' (Sequence ID No. 2) and another oligonucleotide primer consisting of a poly(dC) tail AAGCGGCCGCCCCCCCCCCCCCCCCCCCC-3' (Sequence ID No. 3). Similarly, for cloning of the VL region the poly(dG) tailed first strand DNA was amplified with the antisense primer derived from the 3' end of the light chain constant region 5'-AAGCGGCCGCGAAGATGGATACAGTTGGTGCAGCATCAGC-3' (Sequence ID No. 4) and the other oligonucleotide containing the poly(dC) tail (Sequence ID No. 3). The PCR amplified products which were approximately 400 bp each were separately subcloned into the *Sma*I site of pUC19 plasmid and sequenced by the universal forward and reverse sequencing primers.

The sequences of the heavy and light chain variable region by both methods of cloning (PCR or lambda gt10 library) were found to be identical.

Expression of HPC-4 Fab in bacteria: The Fab (fragment antigen binding) sequence of HPC-4 was amplified from the heavy and light chain cDNA by the PCR methods for expression as outlined briefly below: The Fab region of an antibody is made of VH and the constant heavy chain domain 1 (CH1) held together with VL and the constant light

chain (CL). To express HPC-4 Fab in bacteria, four PCR primers were synthesized: The heavy chain forward primer was 5'-AGGTTACTCTGCTCGAGTCTGGCCCTGG-3' (Sequence ID No. 5) which was designed to have a XhoI restriction enzyme site for construction purposes. The heavy chain reverse primer (complementary to the 3' end of CH1 region) 5'-AGGCCTACTAGTTTACTAACAATCCCTGGGCACAAT-3' (Sequence ID No. 6) was synthesized with two stop codons and an SpeI site after the stop codons. Similarly, a light chain forward primer 5'-TGTCCAGAGGAGAGCTCATTCTCACCCAGTCTCCGGC-3' (Sequence ID No. 7) was synthesized which contained a SacI restriction enzyme site and the reverse primer 5'-TCCTTCTAGATTACTAACACTCTCCCCTGTTGAA-3' (Sequence ID No. 8) contained two stop codons and an XbaI site for construction purposes. The heavy and light chain HPC-4 cDNA were amplified by these primers and the resulting DNA fragments were subcloned into Immuno ZAP HTM and Immuno ZAP LTM vectors, respectively, according to the manufacturer's instruction (Stratagene, CA).

The HPC-4 Fab was expressed in the periplasmic space of bacteria (XL1-B strain of *E. Coli*) and purified on its own 12 residue epitope from human protein C activation peptide region (Glu-Asp-Gln-Val-Asp-Pro-Arg-Leu-Ila-Asp-Gly-Lys (Sequence ID No. 1), linked to AffigelTM. The HPC-4 Fab was eluted with TBS (20 mM Tris HCl, pH 7.5, 0.1 M NaCl) containing 5 mM EDTA, indicating that the binding of Fab fragment of HPC-4 to its epitope, like the full length native HPC-4 antibody, is Ca²⁺ dependent. SDS-PAGE of purified Fab indicated that the purified Fab is essentially pure and as expected it migrated with an apparent molecular mass of 48 KDa. All indications are that recombinant HPC-4 Fab contains all the properties

of wild type HPC-4 monoclonal purified from ascites. It should be noted that the cloning strategies used in Immuno ZAP™ expression system changes the native threonine (amino acid at position 3) to Lysine and Lysine at position 5 to Leucine, in the heavy chain. In the light chain the native HPC-4 contains Glutamine and Isoleucine at the position 1 and 2 of the mature peptide and the cloning strategy changes them to Glutamic acid and Leucine, respectively. These minor changes at the N-terminus of the heavy and light chain which are outside the regions where the epitope binds during expression in bacteria do not effect the properties of HPC-4 Fab as evidenced by its similar Ca²⁺ - dependent affinity binding to the 12 amino acid residue peptide epitope determined by intrinsic fluorescence spectroscopy.

Using these techniques, the following nucleic acid and amino acid sequences were obtained:

1. Nucleotide sequence encoding HPC-4 Heavy chain variable region (VH Gamma) (Sequence ID No. 9):

ATGGGCAGGC TTTCTTCTTC ATTCTTGCTA CTGATTGCCC
 25 CTGCATATGT CCTGTCCCAG GTTACTCTGA AAGAGTCTGG
 CCCTGGGATA TTGCAGCCCT CCCAGACCCT CACTCTGACT
 TGTTCTCTCT CTGGGTTTTTC ACTGAGGACT TCTGGTATGG
 GTGTAGGCTG GATTCGTCAG CCTTCAGGGA AGGGTCTGGA
 GTGGCTGGCA CACATTTGGT GGGATGATGA CAAGCGCTAT
 30 AACCCAGTCC TGAAGAGCCG ACTGATAATC TCCAAGGATA
 CCTCCAGGAA ACAGGTATTC CTCAAGATCG CCAGTGTGGA
 CACTGCAGAT ACTGCCACAT ACTACTGTGT TCGAATGATG
 GATGATTACG ACGCTATGGA CTA CTG GGGT CAAGGAACCT
 CAGTCACCGT CTCCTCT.

35 The signal peptide is encoded by nucleotides 1 to 57. The mature peptide (form that is expressed) is encoded by nucleotides 58 to 417.

2. The HPC-4 heavy chain variable region amino acid sequence including the signal sequence (Sequence ID No. 10) is as follows:

5 MGRLSSSFLL LIAPAYVLSQ VTLKESGPGI LQPSQTLTTLT
 CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA HIWDDDKRY
 NPVLKSRLII SKDTSRKQVF LKIASVDTAD TATYYCVRMM
 DDYDAMDYWG QGTSVTVSS.

The mature peptide starts at amino acid No.
 10 20 which is a Q. Standard one-letter abbreviations for amino acids are used.

3. Nucleotide sequence encoding HPC-4 light chain variable region (VL Kappa) (Sequence ID No. 11) is as follows:

15 ATGGATTTTC AGGTGCAGAT TTCAGCTTC CTGCTAATCA
 GTGCCCTCAGT CATAATGTCC AGAGGACAAA TTATTCTCAC
 CCAGTCTCCG GCAATCATGT CTGCATCTCT GGGGGAGGAG
 ATCACCTAA CCTGCAGTGC CACTTCGAGT GTAACCTACG
 TCCACTGGTA CCAGCAGAAG TCAGGCACTT CTCCAAACT
 20 CTTGATTTAT GGGACATCCA ACCTGGCTTC TGGAGTCCCT
 TCTCGTTTCA GTGGCAGTGG GTCTGGGACC TTTTATTCTC
 TCACAGTCAG CAGTGTGGAG GCTGAAGATG CTGCCGATTA
 TTACTGCCAT CAGTGAATA GTTATCCGCA CACGTTCGGA
 GGGGGGACCA AGCTGGAAAT AAAACGG.

25 The signal peptide is encoded by nucleotides 1 to 66. The mature peptide is encoded by nucleotides 67 to 387 (starts at CAAATTA.....).

4. The HPC-4 light chain variable region amino acid sequence (Kappa chain) (Sequence ID No. 12) is as follows.

30 MDFQVQIFSF LLISASVIMS RGQIILTQSP AIMSASLGEE
 ITLTCSATSS VTYVHWYQQK SGTSPKLLIY GTSNLAGSVP
 SRFSGSGSGT FYSLTVSSVE AEDAADYYCH QWNSYPHTFG
 GGTKLEIKR.

35 The mature peptide starts at amino acid 23 which is a Q.

Those skilled in the art will realize that a variety of DNA sequences would code for the polypeptide antibody fragments described above. This is due to existence of the degeneracy of the genetic code, which means that different codons (sets of three bases) can code for the same amino acid residue. These are known to those skilled in the art. It is also possible to synthesize DNA sequence having different additional substitution than those described above but which would still code for a protein having the same binding specifications, for example, which has conservative amino acid substitutions, i.e., substitutions of one amino acid with another of similar size and charge.

Construction of Recombinant Antibodies.

Using the sequences disclosed above, recombinant antibodies can be constructed using known methodology. Methods for constructing chimeric genes have been described by, for example, Kobilka, B.K., et al, "Chimeric α_2 - β_2 -Adrenergic Receptors: Delineation of Domains Involved in Effector Coupling and Ligand Binding Specificity" Science 240:1310-1316, 1988; Verhoeyen, M., C. Milstein, G. Winter, "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536, 1988; Riechmann, L., M. Clark, H. Waldmann, G. Winter, "Reshaping human antibodies for therapy," Nature, 332:323-327, 1988). Using standard molecular biology techniques, the target DNA, containing the gene for the monoclonal antibody of interest can be constructed into appropriate expression vectors, such as baculovirus expression vectors, according to the procedures described in Summers, M.D. and G.E. Smith, "A manual of methods for baculovirus vectors and insect cell culture procedures", Texas Agricultural

Experimental Station (1987). Expression of the recombinant gene can be achieved by the methods described therein, the teachings of which are incorporated herein. Alternatively, recombinant antibodies can be produced in bacterial periplasmic expression vectors such as those described above. Screening for the desired product can be achieved by ELISA assay wherein released protein is tested for its ability to recognize the antigen for which the target immunoglobulin was specific in a metal dependent manner.

Humanization of Antibodies

Methods for "humanizing" antibodies, or generating less immunogenic fragments of non-human antibodies, are well known. A humanized antibody is one in which only the antigen-recognizing sites, or complementarity-determining hypervariable regions (CDRs) are of non-human origin, whereas all other regions including the framework regions (FRs) of variable domains are products of human genes. These "humanized" antibodies are less immunogenic when introduced into a human recipient yet they retain their antigen binding specificity. To accomplish humanization of a selected mouse monoclonal antibody, the CDR grafting method described by Daugherty, et al., Nucl. Acids Res., 19:2471-2476 (1991), incorporated herein by reference, can be used. Briefly, animal CDRs are distinguished from animal framework regions (FRs) based on locations of the CDRs in known sequences of animal variable genes, (Kabat, H.A., et al., Sequences of Proteins of Immunological Interest, 4th Ed. U.S. Dept. Health and Human Services, Bethesda, MD, 1987). Once the animal CDRs and FRs are identified, the animal CDRs are grafted onto the sequence of an unrelated human heavy and light chain variable region frameworks by the standard

molecular biology techniques including the use of synthetic oligonucleotides and polymerase chain reaction (PCR) methods. Alternatively, the entire sequences of a known human variable heavy and light chain gene in which all the codons encoding for the CDRs are replaced with the desired CDRs of animal antibody, are synthesized in the laboratory by a DNA synthesizer (Applied Biosystems Division of Perkin-Elmer Cetus, CA). The resulting synthetic DNA sequences encoding for the human heavy and light chain variable regions with grafted CDRs from animal antibody are subcloned into expression vectors and recombinant fusion antibodies are prepared in baculovirus or periplasmic space of bacteria as described above. Recombinant antibodies can be produced in mammalian expression systems as well.

The immunogenic stimulus presented by the monoclonal antibodies so produced may be also decreased by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. In the RPAS, the variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. Compared to the intact monoclonal antibody, the recombinant ScFv includes a considerably lower number of antigenic epitopes, and thereby presents a much weaker immunogenic stimulus when injected into humans.

Purification of HPC-4 Antibody

Both HPC-4 from ascites and the recombinant HPC-4 bind to a defined region of the protein C molecule that is contained within
5 residues 6 and 17 of the heavy chain, specifically E D Q V D P R L I D G K (Sequence ID No. 1). This peptide can be immobilized directly on a solid support resin and can be used to isolate the antibody in high concentrations from ascites fluid
10 or as recombinant form from cell culture supernatants. This approach allows the isolation of the antibody in extremely pure form in high yield, even from very dilute solutions.

The antibody can be removed from the
15 solid support peptide either by the removal of calcium ions, if desired, or by 1.5 M guanidine, which does not affect the function of the purified monoclonal antibody. This may be significant, as guanidine is recognized as a viral deactivation
20 agent by regulatory agencies. After elution or treatment with this agent, the antibody will not contain any live virus which may be present either in the ascites fluid derived from the mice used to produce the monoclonal antibody or culture
25 supernatants, if tissue culture for production of recombinant antibody was used. Accordingly, virus will not be introduced into the protein C product from the antibody used to prepare it.

In a preferred embodiment, the peptide is
30 coupled to Affi-Gel™ 15 to give a final concentration of approximately 1.0 mg/ml. Coupling of the epitope peptide is performed in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, at 4°C as described by the manufacturer (Bio-Rad, Richmond, CA). The Affi-Gel™
35 is washed with ice cold water immediately before use to remove the organic solvent. The epitope peptide is prepared at a concentration of

between 1 and 2 mg/ml in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, and mixed with sufficient Affi-Gel™ 15 to give a final ratio of peptide to gel of 1 mg/ml. The peptide and the gel are mixed overnight (between
5 approximately 12 and 18 h) on a gentle rocker to couple the peptide to the gel. After the coupling reaction is completed, the resin is poured into a glass column, and washed with 0.1 M NaCl
10 0.01 M MOPS, pH 7.5. 100 ml of resin has a capacity of at least 1.5 grams of HPC-4.

Human protein C can be coupled to the Affi-Gel™ by the same method. Three to five mg protein C/ml of the buffer described above is mixed with sufficient Affi-Gel™ 15 to give a final ratio
15 of human protein C to gel of 3-5 mg protein/ml of gel.

The desalted ammonium sulfate fraction from the ascites is loaded onto the epitope affinity column, and the column is washed with at
20 least 4 column volumes of 0.4 M NaCl, 0.02 M Tris HCl, 1 mM CaCl₂, pH 7.5. The HPC-4 or recombinant antibody is then eluted from the column in one of the following ways: (1) 2 M NaCl, 0.02 M Tris HCl, 2 mM EDTA; (2) 2 M NaCl, 1.5 M guanidine HCl, 0.02
25 M Tris HCl, 2 mM EDTA. The advantage of the latter is that the protein elutes as a much sharper peak, with concentrations of greater than 25 mg/ml when 200 ml of ascites is applied to a 100 ml column of resin. The antibody retains greater than 95% of
30 the capacity to bind to the epitope after elution under these conditions. Antibody is then either dialyzed or desalted into the appropriate buffer for further applications. No contaminants of the antibody are detectable by SDS gel electrophoresis.
35 Additional antibody can be obtained by applying the breakthrough material back to the column if the

column is overloaded above its capacity.

Applications of HPC-4 Antibody In Vitro

The recombinant antibody can be utilized in the same way as HPC-4 for purification and therapeutic purposes. As discussed below, "HPC-4" includes both the deposited murine monoclonal antibody and recombinant forms thereof.

Purification of Protein C

For purification of protein C by affinity chromatography, coupling of the antibody to an immobilized substrate such as Affi-Gel™ resin is performed in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, at 4°C as described by the manufacturer (Bio-Rad, Richmond, CA). The Affi-Gel™ is washed with ice cold water immediately before use to remove the organic solvent. HPC-4 is prepared at a concentration of 3-5 mg/ml in 0.1 M NaCl, 0.1 M MOPS, pH 7.5, and mixed with sufficient Affi-Gel™ to give a final ratio of HPC-4 to gel of 5 mg/ml. Antibody and the gel are mixed overnight (12-18 h) on a gentle rocker to allow the coupling reaction. Usually greater than 90% of the antibody is bound. After the coupling reaction is completed, the resin is poured into a glass column, and washed with 0.1 M NaCl 0.01 M MOPS, pH 7.5. The resin is stable at 4°C under these conditions for at least one year. 100 ml of resin has a capacity of at least 20 milligrams of protein C.

As described above, the peptide can be used in the isolation and purification of HPC-4 by affinity chromatography. In a similar manner, the peptide can be used to temporarily "protect" the binding site during the process in which the antibody is bound to the chromatography substrate, to insure that the maximum amount of bound antibody is available for binding to the protein to be isolated. The reactive groups of the peptide which

are capable of reacting with the chromatography substrate (amino terminal, lysine side chain), which are not required for recognition by HPC-4, are first blocked by reaction of the peptide with acetic anhydride using standard methods known to those skilled in the art. After the HPC-4 is coupled to the resin, the peptide bound in the antigen binding site of the antibody is removed by washing the resin with 1.5 M Guanidine HCl, 2 mM EDTA, 0.02 M Tris HCl, pH 7.5.

The antibody and peptide can be bound to a variety of substrates, for use in purification and isolation of Protein C and the antibody, respectively, including agarose, acrylamide and other types of conventional chromatographic resins, filters, etc. These materials are known to those skilled in the art, as are the methods for attaching the protein to them. The selection of the material will depend in large part on the scale of the purification or the sample to be analyzed, as well as biocompatibility and government agency approval where the end-product is for pharmaceutical use.

Diagnostic Applications

Methods and means for labeling the antibody for use as a diagnostic are known to those skilled in the art, including labelling with a radioactive, fluorescent, luminescent, or enzymatic molecule. The antibodies are then used in diagnostic assays to measure the amount of Protein C rather than Activated Protein C or total Protein C, since the antibody does not bind Activated Protein C, unlike other antibodies to Protein C.

Isolation of fusion proteins with antibody

A fusion protein readily isolated by affinity chromatography using HPC-4 antibody is

prepared by insertion of a DNA sequence encoding the twelve amino acid HPC-4 epitope into a vector, followed by the gene encoding the protein to be isolated as described in U.S. Patent No. 5,298,599
5 issued March 29, 1994. In the preferred embodiment, a specific protease cleavage site is inserted into the vector between the epitope and protein coding sequence, so that the resulting fusion protein can be easily cleaved to yield the
10 epitope peptide and the desired protein. In the most preferred embodiment, the fusion protein includes a protease cleavage site between the epitope and the protein to be isolated. Suitable sites include sequences cleaved by Factor Xa: Ile
15 Glu Gly Arg (IEGR), enterokinase: Asp Asp Asp Asp Lys (DDDDK), and thrombin: Phe/Gly Pro Arg (F/GPR). Following purification with the HPC-4, the fusion protein is treated with the appropriate enzyme to cleave the binding peptide from the desired
20 protein.

Therapeutic Uses of Recombinant HPC-4

The coagulant and anticoagulant systems in mammals provide a delicate check and balance system which maintains blood in its proper fluid
25 state. Alteration of any single element in this system can have an enormous impact on the ability of the mammal to maintain hemostasis.

The protein C system is an anticoagulant, regulatory system which inhibits blood coagulation
30 and stimulates fibrinolysis. This system is activated by thrombin, an enzyme which converts fibrinogen to fibrin in the coagulative process. Free or excess thrombin binds with thrombomodulin, a protein on endothelial cells. The thrombin-
35 thrombomodulin complex abolishes the ability of thrombin to catalyze clot formation and converts thrombin into a potent protein C activator.

Activated Protein C in turn acts in combination with Protein S and a membrane surface to inactivate factor Va and factor VIIIa by limited proteolysis. The inactivated factor Va loses the ability to
5 interact effectively with the enzyme factor Xa or the substrate prothrombin.

Addition of an antibody to Protein C, an antibody to Protein S, or addition of C4b binding protein (C4bBP), which binds Protein S to thereby
10 inactivate it as a cofactor, in an appropriate form, can be used to promote clotting in individuals where it is desirable to do so. Patients having factor VIII inhibitors are representative of this group of patients. By
15 preventing the factor Va from being inactivated, coagulation proceeds even in the relative absence of factor VIII.

The effect of administering these inhibitors of the Protein C anticoagulation system
20 can be reversed by administration of excess amounts of activated Protein C or Protein S, depending on the agent used to block the pathway. The appropriate amount is based on calculations relating to the relative molar amounts of the
25 proteins present in the blood. The feasibility of this approach to produce a hypercoaguable state has been demonstrated by the administration of HPC-4 to baboons (Taylor, et al, J. Clin. Invest., 79, 918-925 (1987). When HPC-4 was present, the animals
30 developed a massive coagulation response, characterized by total fibrinogen consumption, as the result of the infusion of low levels of bacteria. They did not develop this response in the absence of the antibody. Virtually identical
35 results are obtained when C4bBP levels are elevated to approximately 1 mg/ml plasma. While these responses are detrimental to the animals, they

illustrate that either method will enhance the coagulation system. This is beneficial in situations where normal hemostasis is impaired.

5 This method can also be applied in the treatment of other clotting factor deficiency states, including thrombocytopenia, for example, as induced by heparin or radiation therapy, liver disease and hemorrhagic stroke, both acutely and to minimize re-bleeding after the acute incident.

10 HPC-4 can also be used to induce microvascular clotting in a solid tumor bed, as described in U.S. Patent No. 5,147,638 issued September 5, 1992. In animal tumor models, this has been found to greatly impede growth of the
15 tumor. The combination of this antibody and/or the other agents indicated above which are capable of blocking the function of the protein C anticoagulant pathway with other treatments presently in use, such as tumor necrosis factor or
20 radiation, can also be used for treatment of solid tumors.

Pharmaceutical Compositions

Pharmaceutically acceptable carriers for administration of the antibodies include sterile
25 normal saline at physiological pH. In the preferred method of administration, the agent is injected into the subject, most preferably, intravenously. Preferred dosages are between about 30 and about 150 μg antibody/ml patient plasma,
30 which is sufficient to block greater than 90% of the endogenous protein C.

The teachings of the references and patents cited above are specifically incorporated herein as representative of methods and reagents
35 known to those skilled in the art.

- (ii) MOLECULE TYPE: DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGCGGCCGC CCCCCCCCC CCCCCCCCC 30

- (2) INFORMATION FOR SEQ ID NO:4:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: YES
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAGCGGCCGC GAAGATGGAT ACAGTTGGTG CAGCATCAGC 40

- (2) INFORMATION FOR SEQ ID NO:5:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AGTTACTCT GCTCGAGTCT GGCCCTGG 28

- (2) INFORMATION FOR SEQ ID NO:6:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AGGCCTACTA GTTTACTAAC AATCCCTGGG CACAAT 36

- (2) INFORMATION FOR SEQ ID NO:7:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 37 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TGTCCAGAGG AGAGCTCATT CTCACCCAGT CTCCGGC 37

- (2) INFORMATION FOR SEQ ID NO:8:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 34 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA
 - (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TCCTTCTAGA TTAATAACAC TCTCCCCTGT TGAA 34

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 417 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: HPC-4 Heavy Chain Variable Region (VH Gamma)
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 1..57
 - (D) OTHER INFORMATION: /note= "Signal peptide encoded by nucleotides 1 through 57."
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 58..417
 - (D) OTHER INFORMATION: /note= "Mature peptide encoded by nucleotides 58 through 417."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGGGCAGGC TTTCTTCTTC ATTCTTGCTA CTGATTGCC CTGCATATGT CCTGTCCCAG 60
 GTTACTCTGA AAGAGTCTGG CCCTGGGATA TTGCAGCCCT CCCAGACCCT CACTCTGACT 120
 TGTTCTCTCT CTGGGTTTTCT ACTGAGGACT TCTGGTATGG GTGTAGGCTG GATTTCGTCAG 180
 CCTTCAGGGA AGGGTCTGGA GTGGCTGGCA CACATTTGGT GGGATGATGA CAAGCGCTAT 240
 AACCCAGTCC TGAAGAGCCG ACTGATAATC TCCAAGGATA CCTCCAGGAA ACAGGTATTC 300
 CTCAAGATCG CCAGTGTGGA CACTGCAGAT ACTGCCACAT ACTACTGTGT TCGAATGATG 360
 GATGATTACG ACGCTATGGA CTA CTGGGGT CAAGGAACCT CAGTCACCGT CTCCTCT 417

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 139 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: HPC-4 Heavy Chain Variable Region (VH Gamma)
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 20..139
 - (D) OTHER INFORMATION: /note= "Gln at position 20 starts mature peptide."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Gly Arg Leu Ser Ser Ser Phe Leu Leu Leu Ile Ala Pro Ala Tyr
 1 5 10 15
 Val Leu Ser Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln
20 25 30

Pro Ser Gln Thr Leu Thr Leu Thr Cys Ser Leu Ser Gly Phe Ser Leu
 35 40 45
 Arg Thr Ser Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys
 50 55 60
 Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Arg Tyr
 65 70 75 80
 Asn Pro Val Leu Lys Ser Arg Leu Ile Ile Ser Lys Asp Thr Ser Arg
 85 90 95
 Lys Gln Val Phe Leu Lys Ile Ala Ser Val Asp Thr Ala Asp Thr Ala
 100 105 110
 Thr Tyr Tyr Cys Val Arg Met Met Asp Asp Tyr Asp Ala Met Asp Tyr
 115 120 125
 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 130 135

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 387 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: HPC-4 Light Chain Variable Region (VL Kappa)
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 1..66
 - (D) OTHER INFORMATION: /note= "Signal peptide encoded by nucleotides 1 through 66."
- (ix) FEATURE:
 - (A) NAME/KEY: misc_feature
 - (B) LOCATION: 67..387
 - (D) OTHER INFORMATION: /note= "Mature peptide encoded by nucleotides 67 through 387."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATGGATTTTC AGGTGCAGAT TTTCAGCTTC CTGCTAATCA GTGCCTCAGT CATAATGTCC 60
 AGAGGACAAA TTATTCTCAC CCAGTCTCCG GCAATCATGT CTGCATCTCT GGGGGAGGAG 120
 ATCACCCCTAA CCTGCAGTGC CACTTCGAGT GTAACCTACG TCCACTGGTA CCAGCAGAAG 180
 TCAGGCACTT CTCCCAAACCT CTTGATTTAT GGGACATCCA ACCTGGCTTC TGGAGTCCCT 240
 TCTCGTTTCA GTGGCAGTGG GTCTGGGACC TTTTATTCTC TCACAGTCAG CAGTGTGGAG 300
 GCTGAAGATG CTGCCGATTA TTAAGTCCAT CAGTGAATA GTTATCCGCA CAGGTTCCGA 360
 GGGGGGACCA AGCTGGAAAT AAAACGG 387

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 129 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

28

- (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: HPC-4 Light Chain Variable Region (VL Kappa)
 (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION: 23..129
 (D) OTHER INFORMATION: /note= "Gln at position 23 starts
 mature peptide."
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1                               5                               10          15

Val Ile Met Ser Arg Gly Gln Ile Ile Leu Thr Gln Ser Pro Ala Ile
                20                               25          30

Met Ser Ala Ser Leu Gly Glu Glu Ile Thr Leu Thr Cys Ser Ala Thr
          35                               40          45

Ser Ser Val Thr Tyr Val His Trp Tyr Gln Gln Lys Ser Gly Thr Ser
 50                               55          60

Pro Lys Leu Leu Ile Tyr Gly Thr Ser Asn Leu Ala Ser Gly Val Pro
 65                               70          75          80

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Phe Tyr Ser Leu Thr Val
          85                               90          95

Ser Ser Val Glu Ala Glu Asp Ala Ala Asp Tyr Tyr Cys His Gln Trp
          100                              105          110

Asn Ser Tyr Pro His Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
          115                              120          125

Arg

```

We claim:

1. A recombinant Ca²⁺ dependent monoclonal antibody immunoreactive with an epitope in the activation peptide region of the heavy chain of Protein C defined by E D Q V D P R L I D G K (Sequence ID No. 1) in combination with calcium, where the antibody inhibits Protein C activation by thrombin-thrombomodulin.
2. The antibody of claim 1 comprising amino acid sequence selected from the group consisting of:

MGR LSSS FLL LIAPAYVLSQ VTLKESGPGI LQPSQTLTTLT
 CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA HIWDDDKRY
 NPVLKSRLII SKDTSRKQVF LKIASVDTAD TATYYCVRMM
 DDYDAMDYWG QGTSVTVSS (Sequence ID No. 10);
 MDFQVQIFSF LLISASVIMS RGQIILTQSP AIMSASLGEE
 ITLTCSATSS VTYVHWYQQK SGTSPKLLIY GTSNLAGVGP
 SRFSGSGSGT FYSLTVSSVE AEDAADYCH QWNSYPHTFG
 GGTKLEIKR (Sequence ID No. 12); Q VTLKESGPGI
 LQPSQTLTTLT CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA
 HIWDDDKRY NPVLKSRLII SKDTSRKQVF LKIASVDTAD
 TATYYCVRMM DDYDAMDYWG QGTSVTVSS (amino acids 20-139
 of Sequence ID No. 10) and QIILTQSP AIMSASLGEE
 ITLTCSATSS VTYVHWYQQK SGTSPKLLIY GTSNLAGVGP
 SRFSGSGSGT FYSLTVSSVE AEDAADYCH QWNSYPHTFG
 GGTKLEIKR (amino acids 23-129 of Sequence ID No.
 12).
3. The antibody of claim 1 containing human amino acid sequence.
4. The antibody of claim 1 encoded in part by a nucleotide sequence selected from the group consisting of ATGGGCAGGC TTTCTTCTTC ATTCTTGCTA CTGATTGCCC CTGCATATGT CCTGTCCCAG GTTACTCTGA AAGAGTCTGG CCCTGGGATA TTGCAGCCCT CCCAGACCCT CACTCTGACT TGTCTCTCTCT CTGGGTTTTTC ACTGAGGACT TCTGGTATGG GTGTAGGCTG GATTCGTCAG CCTTCAGGGA AGGGTCTGGA GTGGCTGGCA CACATTTGGT

GGGATGATGA CAAGCGCTAT AACCCAGTCC TGAAGAGCCG
 ACTGATAATC TCCAAGGATA CCTCCAGGAA ACAGGTATTC
 CTCAAGATCG CCAGTGTGGA CACTGCAGAT ACTGCCACAT
 ACTACTGTGT TCGAATGATG GATGATTACG ACGCTATGGA
 5 CTACTGGGGT CAAGGAACCT CAGTCACCGT CTCCTCT (Sequence
 ID No. 9); CAG GTTACTCTGA AAGAGTCTGG CCCTGGGATA
 TTGCAGCCCT CCCAGACCCT CACTCTGACT TGTTCTCTCT
 CTGGGTTTTT ACTGAGGACT TCTGGTATGG GTGTAGGCTG
 GATTCGTCAG CCTTCAGGGA AGGGTCTGGA GTGGCTGGCA
 10 CACATTTGGT GGGATGATGA CAAGCGCTAT AACCCAGTCC
 TGAAGAGCCG ACTGATAATC TCCAAGGATA CCTCCAGGAA
 ACAGGTATTC CTCAAGATCG CCAGTGTGGA CACTGCAGAT
 ACTGCCACAT ACTACTGTGT TCGAATGATG GATGATTACG
 ACGCTATGGA CTACTGGGGT CAAGGAACCT CAGTCACCGT CTCCTCT
 15 (nucleotides 58 to 417 of Sequence ID No. 9);
 ATGGATTTTC AGGTGCAGAT TTTCAGCTTC CTGCTAATCA
 GTGCCTCAGT CATAATGTCC AGAGGACAAA TTATTCTCAC
 CCAGTCTCCG GCAATCATGT CTGCATCTCT GGGGGAGGAG
 ATCACCCCTAA CCTGCAGTGC CACTTCGAGT GTAACCTACG
 20 TCCACTGGTA CCAGCAGAAG TCAGGCACTT CTCCCAAACCT
 CTTGATTTAT GGGACATCCA ACCTGGCTTC TGGAGTCCCT
 TCTCGTTTCA GTGGCAGTGG GTCTGGGACC TTTTATTCTC
 TCACAGTCAG CAGTGTGGAG GCTGAAGATG CTGCCGATTA
 TTACTGCCAT CAGTGAATA GTTATCCGCA CACGTTCGGA
 25 GGGGGGACCA AGCTGGAAAT AAAACGG (Sequence ID No. 11);
 CAAA TTATTCTCAC CCAGTCTCCG GCAATCATGT CTGCATCTCT
 GGGGGAGGAG ATCACCCCTAA CCTGCAGTGC CACTTCGAGT
 GTAACCTACG TCCACTGGTA CCAGCAGAAG TCAGGCACTT
 CTCCCAAACCT CTTGATTTAT GGGACATCCA ACCTGGCTTC
 30 TGGAGTCCCT TCTCGTTTCA GTGGCAGTGG GTCTGGGACC
 TTTTATTCTC TCACAGTCAG CAGTGTGGAG GCTGAAGATG
 CTGCCGATTA TTACTGCCAT CAGTGAATA GTTATCCGCA
 CACGTTCGGA GGGGGGACCA AGCTGGAAAT AAAACGG
 (nucleotides 67 to 387 of Sequence ID No. 11); and
 35 degenerate sequences thereof.

5. The antibody of claim 1 further comprising a pharmaceutically acceptable carrier for administration to a patient.

6. The antibody of claim 5 further comprising a cytokine or an inducer of cytokine expression in a dosage effective in combination with the antibody to coagulate microvasculature in tumors but not in the absence of the antibody.

7. The antibody of claim 1 having a detectable label bound to the antibody.

8. The antibody of claim 1 immobilized to a substrate, wherein the immobilized antibody is suitable for purification of protein C from a biological fluid.

9. A method for treating a disorder by inhibition of protein C anticoagulant comprising administering to a patient in need of treatment thereof an effective amount of a recombinant Ca^{2+} dependent monoclonal antibody immunoreactive with an epitope in the activation peptide region of the heavy chain of Protein C defined by E D Q V D P R L I D G K (Sequence ID No. 1) in combination with calcium, where the antibody inhibits Protein C activation by thrombin-thrombomodulin.

10. The method of claim 9 wherein the antibody comprises amino acid sequence selected from the group consisting of:

MGR LSSS FLL LIAPAYVLSQ VTLKESGPGI LQPSQTLTLT
 CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA HIWDDDKRY
 NPVLKSRLII SKDTSRKQVF LKIASVDTAD TATYYCVRMM
 DDYDAMDYWG QGTSVTVSS (Sequence ID No. 10);
 MDFVQVIFSF LLISASVIMS RGQIILTQSP AIMSASLGEE
 ITLTC SATSS VTYVHWYQQK SGTSPKLLIY GTSNLASGVP
 SRFSGSGSGT FYSLTVSSVE AEDAADYYCH QWNSYPHTFG
 GGTKLEIKR (Sequence ID No. 12); Q VTLKESGPGI
 LQPSQTLTLT CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA
 HIWDDDKRY NPVLKSRLII SKDTSRKQVF LKIASVDTAD

TATYYCVRMM DDYDAMDYWG QGTSVTVSS (amino acids 20-139
of Sequence ID No. 10) and QIILTQSP AIMSASLGEE
ITLTCSATSS VTYVHWYQOK SGTSPKLLIY GTSNLAGSVP
SRFSGSGSGT FYSLTVSSVE AEDAADYYCH QWNSYPHTFG
5 GGTKLEIKR (amino acids 23-129 of Sequence ID No.
12).

11. The method of claim 9 wherein the
antibody contains human amino acid sequence.

12. The method of claim 9 wherein the
10 antibody is encoded in part by a nucleotide
sequence selected from the group consisting of
ATGGGCAGGC TTTCTTCTTC ATTCTTGCTA CTGATTGCCC
CTGCATATGT CCTGTCCCAG GTTACTCTGA AAGAGTCTGG
CCCTGGGATA TTGCAGCCCT CCCAGACCCT CACTCTGACT
15 TGTTCTCTCT CTGGGTTTTT ACTGAGGACT TCTGGTATGG
GTGTAGGCTG GATTCGTCAG CCTTCAGGGA AGGGTCTGGA
GTGGCTGGCA CACATTTGGT GGGATGATGA CAAGCGCTAT
AACCCAGTCC TGAAGAGCCG ACTGATAATC TCCAAGGATA
CCTCCAGGAA ACAGGTATTC CTCAAGATCG CCAGTGTGGA
20 CACTGCAGAT ACTGCCACAT ACTACTGTGT TCGAATGATG
GATGATTACG ACGCTATGGA CTACTGGGGT CAAGGAACCT
CAGTCACCGT CTCCTCT (Sequence ID No. 9); CAG
GTTACTCTGA AAGAGTCTGG CCCTGGGATA TTGCAGCCCT
CCCAGACCCT CACTCTGACT TGTTCTCTCT CTGGGTTTTT
25 ACTGAGGACT TCTGGTATGG GTGTAGGCTG GATTCGTCAG
CCTTCAGGGA AGGGTCTGGA GTGGCTGGCA CACATTTGGT
GGGATGATGA CAAGCGCTAT AACCCAGTCC TGAAGAGCCG
ACTGATAATC TCCAAGGATA CCTCCAGGAA ACAGGTATTC
CTCAAGATCG CCAGTGTGGA CACTGCAGAT ACTGCCACAT
30 ACTACTGTGT TCGAATGATG GATGATTACG ACGCTATGGA
CTACTGGGGT CAAGGAACCT CAGTCACCGT CTCCTCT
(nucleotides 58 to 417 of Sequence ID No. 9);
ATGGATTTTC AGGTGCAGAT TTTCAGCTTC CTGCTAATCA
GTGCCTCAGT CATAATGTCC AGAGGACAAA TTATTCTCAC
35 CCAGTCTCCG GCAATCATGT CTGCATCTCT GGGGGAGGAG
ATCACCCATA CCTGCAGTGC CACTTCGAGT GTAACCTACG
TCCACTGGTA CCAGCAGAAG TCAGGCACTT CTCCCAA

CTTGATTTAT GGGACATCCA ACCTGGCTTC TGGAGTCCCT
 TCTCGTTTCA GTGGCAGTGG GTCTGGGACC TTTTATTCTC
 TCACAGTCAG CAGTGTGGAG GCTGAAGATG CTGCCGATTA
 TTACTGCCAT CAGTGGGAATA GTTATCCGCA CACGTTCGGA
 5 GGGGGGACCA AGCTGGAAAT AAAACGG (Sequence ID No. 11);
 CAAA TTATTCTCAC CCAGTCTCCG GCAATCATGT CTGCATCTCT
 GGGGGAGGAG ATCACCCCTAA CCTGCAGTGC CACTTCGAGT
 GTAACCTACG TCCACTGGTA CCAGCAGAAG TCAGGCACTT
 CTCCCAAACCT CTTGATTTAT GGGACATCCA ACCTGGCTTC
 10 TGGAGTCCCT TCTCGTTTCA GTGGCAGTGG GTCTGGGACC
 TTTTATTCTC TCACAGTCAG CAGTGTGGAG GCTGAAGATG
 CTGCCGATTA TTACTGCCAT CAGTGGGAATA GTTATCCGCA
 CACGTTCGGA GGGGGGACCA AGCTGGAAAT AAAACGG
 (nucleotides 67 to 387 of Sequence ID No. 11); and
 15 degenerate sequences thereof.

13. The method of claim 9 further
 comprising administering with the antibody a
 cytokine or other chemotherapeutic agent in an
 amount effective to coagulate the microvasculature
 20 of a tumor.

14. A method of making a recombinant Ca^{2+}
 dependent monoclonal antibody immunoreactive with
 an epitope in the activation peptide region of the
 heavy chain of Protein C defined by E D Q V D P R L
 25 I D G K (Sequence ID No. 1) in combination with
 calcium, where the antibody inhibits Protein C
 activation by thrombin-thrombomodulin, by
 expressing nucleotide sequence encoding the
 antibody.

15. The method of claim 14 wherein the
 antibody comprises amino acid sequence selected
 from the group consisting of:

30 MGRLSSSFLL LIAPAYVLSQ VTLKESGPGI LQPSQTLTLT
 CSLSGFSLRT SGMGVGWIRQ PSGKLEWLA HIWDDDKRY
 35 NPVLKSRLLI SKDTSRKQVF LKIASVDTAD TATYYCVRMM
 DDYDAMDYWG QGTSVTVSS (Sequence ID No. 10);
 MDFQVQIFSF LLISASVIMS RQIILTQSP AIMSASLGEE

ITLTCSATSS VTYVHWYQQK SGTSPKLLIY GTSNLAGV
 SRFSGSGSGT FYSLTVSSVE AEDAADYYCH QWNSYPHTFG
 GGTKLEIKR (Sequence ID No. 12); Q VTLKESGPGI
 LQPSQTLTTL CSLSGFSLRT SGMGVGWIRQ PSGKGLEWLA
 5 HIWWDKRY NPVLKSRLLI SKDTSRKQVF LKIASVDTAD
 TATYYCVRMM DDYDAMDYWG QGTSVTVSS (amino acids 20-139
 of Sequence ID No. 10) and QIILTQSP AIMSASLGEE
 ITLTCSATSS VTYVHWYQQK SGTSPKLLIY GTSNLAGV
 SRFSGSGSGT FYSLTVSSVE AEDAADYYCH QWNSYPHTFG
 10 GGTKLEIKR (amino acids 23-129 of Sequence ID No.
 12).

16. The method of claim 14 wherein the
 antibody is encoded in part by a nucleotide
 sequence selected from the group consisting of
 15 ATGGGCAGGC TTTCTTCTTC ATTCTTGCTA CTGATTGCCC
 CTGCATATGT CCTGTCCCAG GTTACTCTGA AAGAGTCTGG
 CCCTGGGATA TTGCAGCCCT CCCAGACCCT CACTCTGACT
 TGTTCTCTCT CTGGGTTTTT ACTGAGGACT TCTGGTATGG
 GTGTAGGCTG GATTCGTCAG CCTTCAGGGA AGGGTCTGGA
 20 GTGGCTGGCA CACATTTGGT GGGATGATGA CAAGCGCTAT
 AACCCAGTCC TGAAGAGCCG ACTGATAATC TCCAAGGATA
 CCTCCAGGAA ACAGGTATTC CTCAAGATCG CCAGTGTGGA
 CACTGCAGAT ACTGCCACAT ACTACTGTGT TCGAATGATG
 GATGATTACG ACGCTATGGA CTACTGGGGT CAAGGAACCT
 25 CAGTCACCGT CTCCTCT (Sequence ID No. 9); CAG
 GTTACTCTGA AAGAGTCTGG CCCTGGGATA TTGCAGCCCT
 CCCAGACCCT CACTCTGACT TGTTCTCTCT CTGGGTTTTT
 ACTGAGGACT TCTGGTATGG GTGTAGGCTG GATTCGTCAG
 CCTTCAGGGA AGGGTCTGGA GTGGCTGGCA CACATTTGGT
 30 GGGATGATGA CAAGCGCTAT AACCCAGTCC TGAAGAGCCG
 ACTGATAATC TCCAAGGATA CCTCCAGGAA ACAGGTATTC
 CTCAAGATCG CCAGTGTGGA CACTGCAGAT ACTGCCACAT
 ACTACTGTGT TCGAATGATG GATGATTACG ACGCTATGGA
 CTACTGGGGT CAAGGAACCT CAGTCACCGT CTCCTCT
 35 (nucleotides 58 to 417 of Sequence ID No. 9);
 ATGGATTTTC AGGTGCAGAT TTTCAGCTTC CTGCTAATCA
 GTGCCTCAGT CATAATGTCC AGAGGACAAA TTATTCTCAC

CCAGTCTCCG GCAATCATGT CTGCATCTCT GGGGGAGGAG
ATCACCCCTAA CCTGCAGTGC CACTTCGAGT GTAACCTACG
TCCACTGGTA CCAGCAGAAG TCAGGCACTT CTCCCAAACCT
CTTGATTTAT GGGACATCCA ACCTGGCTTC TGGAGTCCCT
5 TCTCGTTTCA GTGGCAGTGG GTCTGGGACC TTTTATTCTC
TCACAGTCAG CAGTGTGGAG GCTGAAGATG CTGCCGATTA
TTACTGCCAT CAGTGAATA GTTATCCGCA CACGTTCCGA
GGGGGGACCA AGCTGGAAAT AAAACGG (Sequence ID No. 11);
CAAA TTATTCTCAC CCAGTCTCCG GCAATCATGT CTGCATCTCT
10 GGGGGAGGAG ATCACCCCTAA CCTGCAGTGC CACTTCGAGT
GTAACCTACG TCCACTGGTA CCAGCAGAAG TCAGGCACTT
CTCCCAAACCT CTTGATTTAT GGGACATCCA ACCTGGCTTC
TGGAGTCCCT TCTCGTTTCA GTGGCAGTGG GTCTGGGACC
TTTTATTCTC TCACAGTCAG CAGTGTGGAG GCTGAAGATG
15 CTGCCGATTA TTACTGCCAT CAGTGAATA GTTATCCGCA
CACGTTCCGA GGGGGACCA AGCTGGAAAT AAAACGG
(nucleotides 67 to 387 of Sequence ID No. 11); and
degenerate sequences thereof.

17. The method of claim 14 further
20 comprising inserting human sequence into the
antibody in place of animal sequence.

18. The method of claim 14 further
comprising binding detectable lable to the
antibody.

25 19. The method of claim 14 further
comprising immobilizing the antibody to a
substrate, wherein the immobilized antibody is
suitable for purification of protein C from a
biological fluid.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/07372

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/13 C07K16/40 C07K16/46 C07K17/00 A61K39/395
 A61K33/06 A61K38/19 //(A61K39/395,33:06), (A61K39/395,38:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,90 07524 (OKLAHOMA MEDICAL RESEARCH FOUNDATION) 12 July 1990 cited in the application see the whole document ---	1,3,5-9, 11,13, 14,17-19
Y	NUCLEIC ACIDS RESEARCH, vol. 19, no. 9, 11 May 1991 OXFORD, GB, pages 2471-2476, B. DAUGHERTY ET AL. 'Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins.' cited in the application see the whole document ---	1,3,5-9, 11,13, 14,17-19
	-/--	

Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--	--

Date of the actual completion of the international search 16 October 1995	Date of mailing of the international search report 14.11.1995
--	--

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer Nooij, F
---	------------------------------------

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 95/07372

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,91 01753 (OKLAHOMA MEDICAL RESEARCH FOUNDATION) 21 February 1991 cited in the application see examples see claims ---	1,3,5-9, 11,13, 14,17-19
Y	NATURE, vol. 332, no. 6162, 24 March 1988 LONDON, GB, pages 323-327, L. RIECHMANN ET AL. 'Reshaping human antibodies for therapy.' cited in the application see the whole document ---	1,3,5-9, 11,13, 14,17-19
A	WO,A,94 02172 (OKLAHOMA MEDICAL RESEARCH FOUNDATION) 3 February 1994 see example see claims ---	1,9
A	BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1161, no. 2-3, 13 February 1993 AMSTERDAM, NL, pages 113-123, M. TAKAHASHI ET AL. 'Epitope mapping and characterization of monoclonal antibodies to human protein C.' see abstract -----	1,5,7-9, 14,18,19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/07372

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 9-13
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 9-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In tional Application No
PCT/US 95/07372

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9007524	12-07-90	AT-T- 122057	15-05-95
		AU-B- 4422893	27-01-94
		AU-B- 641634	30-09-93
		AU-B- 4968390	01-08-90
		CA-A- 2006684	30-06-90
		DE-D- 68922491	08-06-95
		EP-A- 0407544	16-01-91
		JP-T- 3504332	26-09-91
		KR-B- 9402033	14-03-94
		US-A- 5147638	15-09-92
		US-A- 5202253	13-04-93
		US-A- 5298599	29-03-94
		US-A- 5336610	09-08-94
WO-A-9101753	21-02-91	US-A- 5147638	15-09-92
		AU-B- 639014	15-07-93
		AU-B- 6164390	11-03-91
		CA-A- 2064585	05-02-91
		EP-A- 0489048	10-06-92
		JP-B- 7029937	05-04-95
		JP-T- 4504264	30-07-92
WO-A-9402172	03-02-94	AU-B- 4784693	14-02-94
		EP-A- 0651655	10-05-95